Hospital and community-acquired methicillin-resistant Staphylococcus Aureus bone and joint infections

Methicillin-Resistant Staphylococcus Aureus (MRSA): Etiology, At-Risk Populations and Treatment

Volumn , Issue , 2009, Pages 143-209

  Uçkay, Ilker ^a,b   Laurent, Frederic ^c,d   Lustig, Sébastien ^d,e   Rasigade, Jean Philippe ^c,d   Thomson, Vivien ^d,f   Paoli, Vincent ^d,e   Perpoint, Thomas ^d,f   Stern, Richard ^a   Boibieux, André ^f   Ader, Florence ^c,d,f   Lina, Gerard ^c,d   Lew, Daniel ^a,b   Vandenesch, François ^c,d   Peyramond, Dominique ^d,f   Chidiac, Christian ^c,d,f   Etienne, Jerôme ^c,d   Ferry, Tristan ^c,d,f  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c INSERM   (France)

^d UNIVERSITÉ LYON 1   (France)

^e HOSPICES CIVILS DE LYON   (France)

^f CROIX ROUSSE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84877137419     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (269)

1. Brun-Buisson C, Meshaka P, Pinton P, Vallet B. EPISEPSIS: a reappraisal of theepidemiology and outcome of severe sepsis in French intensive care units. IntensiveCare Med. 2004 Apr;30(4):580-8.
2. Oliveira DC, Tomasz A, de Lencastre H. The evolution of pandemic clones ofmethicillin-resistant Staphylococcus aureus: identification of two ancestral geneticbackgrounds and the associated mec elements. Microb Drug Resist. 2001 Winter;7(4):349-61.
3. Robinson DA, Enright MC. Multilocus sequence typing and the evolution ofmethicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2004 Feb;10(2):92-7.
4. Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG. Multilocus sequence typingfor characterization of methicillin-resistant and methicillin-susceptible clones ofStaphylococcus aureus. J Clin Microbiol. 2000 Mar;38(3):1008-15.
5. Enright MC, Spratt BG. Multilocus sequence typing. Trends Microbiol. 1999 Dec;7(12):482-7.
6. Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, Urwin R, et al. Multilocussequence typing: a portable approach to the identification of clones within populationsof pathogenic microorganisms. Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3140-5.
7. Frenay HM, Bunschoten AE, Schouls LM, van Leeuwen WJ, Vandenbroucke-Grauls CM, Verhoef J, et al. Molecular typing of methicillin-resistant Staphylococcus aureuson the basis of protein A gene polymorphism. Eur J Clin Microbiol Infect Dis. 1996 Jan;15(1):60-4.
8. Shopsin B, Gomez M, Montgomery SO, Smith DH, Waddington M, Dodge DE, et al. Evaluation of protein A gene polymorphic region DNA sequencing for typing ofStaphylococcus aureus strains. J Clin Microbiol. 1999 Nov;37(11):3556-63.
9. Milheirico C, Oliveira DC, de Lencastre H. Multiplex PCR strategy for subtyping thestaphylococcal cassette chromosome mec type IV in methicillin-resistantStaphylococcus aureus: 'SCCmec IV multiplex'. J Antimicrob Chemother. 2007 Jul;60(1):42-8.
10. Milheirico C, Oliveira DC, de Lencastre H. Update to the multiplex PCR strategy forassignment of mec element types in Staphylococcus aureus. Antimicrob AgentsChemother. 2007 Sep;51(9):3374-7.
11. Oliveira DC, de Lencastre H. Multiplex PCR strategy for rapid identification ofstructural types and variants of the mec element in methicillin-resistant Staphylococcusaureus. Antimicrob Agents Chemother. 2002 Jul;46(7):2155-61.
12. Ferry T, Bes M, Dauwalder O, Meugnier H, Lina G, Forey F, et al. Toxin gene contentof the Lyon methicillin-resistant Staphylococcus aureus clone compared with that ofother pandemic clones. J Clin Microbiol. 2006 Jul;44(7):2642-4.
13. Melter O, Santos Sanches I, Schindler J, Aires de Sousa M, Mato R, Kovarova V, et al. Methicillin-resistant Staphylococcus aureus clonal types in the Czech Republic. J ClinMicrobiol. 1999 Sep;37(9):2798-803.
14. Laupland KB, Church DL, Mucenski M, Sutherland LR, Davies HD. Population-basedstudy of the epidemiology of and the risk factors for invasive Staphylococcus aureusinfections. J Infect Dis. 2003 May 1;187(9):1452-9.
15. Harbarth S, Fankhauser C, Schrenzel J, Christenson J, Gervaz P, Bandiera-Clerc C, etal. Universal screening for methicillin-resistant Staphylococcus aureus at hospitaladmission and nosocomial infection in surgical patients. Jama. 2008 Mar12;299(10):1149-57.
16. Boyce JM. Methicillin-resistant Staphylococcus aureus. Detection, epidemiology, andcontrol measures. Infect Dis Clin North Am. 1989 Dec;3(4):901-13.
17. Harbarth S, Sax H, Uckay I, Fankhauser C, Agostinho A, Christenson JT, et al. Apredictive model for identifying surgical patients at risk of methicillin-resistantStaphylococcus aureus carriage on admission. J Am Coll Surg. 2008 Nov;207(5):683-9.
18. Lew DP, Waldvogel FA. Osteomyelitis. Lancet. 2004 Jul 24-30;364(9431):369-79.
19. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998 Aug 20;339(8):520-32.
20. Anderson DJ, Chen LF, Schmader KE, Sexton DJ, Choi Y, Link K, et al. Poorfunctional status as a risk factor for surgical site infection due to methicillin-resistantStaphylococcus aureus. Infect Control Hosp Epidemiol. 2008 Sep;29(9):832-9.
21. Shukla S, Nixon M, Acharya M, Korim MT, Pandey R. Incidence of MRSA surgicalsiteinfection in MRSA carriers in an orthopaedic trauma unit. J Bone Joint Surg Br. 2009 Feb;91(2):225-8.
22. Shirtliff ME, Mader JT. Acute septic arthritis. Clin Microbiol Rev. 2002 Oct;15(4):527-44.
23. Ozuna RM, Delamarter RB. Pyogenic vertebral osteomyelitis and postsurgical discspace infections. Orthop Clin North Am. 1996 Jan;27(1):87-94.
24. Cierny G, 3rd, Mader JT, Penninck JJ. A clinical staging system for adult osteomyelitis. Clin Orthop Relat Res. 2003 Sep(414):7-24.
25. Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: a review of clinical features,therapeutic considerations and unusual aspects. 3. Osteomyelitis associated withvascular insufficiency. N Engl J Med. 1970 Feb 5;282(6):316-22.
26. Cottle L, Riordan T. Infectious spondylodiscitis. J Infect. 2008 Jun;56(6):401-12.
27. Foster TJ, Hook M. Surface protein adhesins of Staphylococcus aureus. TrendsMicrobiol. 1998 Dec;6(12):484-8.
28. Elasri MO, Thomas JR, Skinner RA, Blevins JS, Beenken KE, Nelson CL, et al. Staphylococcus aureus collagen adhesin contributes to the pathogenesis ofosteomyelitis. Bone. 2002 Jan;30(1):275-80.
29. Gemmell CG, Goutcher SC, Reid R, Sturrock RD. Role of certain virulence factors in amurine model of Staphylococcus aureus arthritis. J Med Microbiol. 1997 Mar;46(3):208-13.
30. Palmqvist N, Foster T, Tarkowski A, Josefsson E. Protein A is a virulence factor inStaphylococcus aureus arthritis and septic death. Microb Pathog. 2002 Nov;33(5):239-49.
31. Palmqvist N, Josefsson E, Tarkowski A. Clumping factor A-mediated virulence duringStaphylococcus aureus infection is retained despite fibrinogen depletion. MicrobesInfect. 2004 Feb;6(2):196-201.
32. Ferry T, Perpoint T, Vandenesch F, Etienne J. Virulence determinants inStaphylococcus aureus and their involvement in clinical syndromes. Curr Infect DisRep. 2005 Nov;7(6):420-8.
33. Brady RA, Leid JG, Calhoun JH, Costerton JW, Shirtliff ME. Osteomyelitis and therole of biofilms in chronic infection. FEMS Immunol Med Microbiol. 2008 Jan;52(1):13-22.
34. Proctor RA, von Eiff C, Kahl BC, Becker K, McNamara P, Herrmann M, et al. Smallcolony variants: a pathogenic form of bacteria that facilitates persistent and recurrentinfections. Nat Rev Microbiol. 2006 Apr;4(4):295-305.
35. Sendi P, Proctor RA. Staphylococcus aureus as an intracellular pathogen: the role ofsmall colony variants. Trends Microbiol. 2009 Feb;17(2):54-8.
36. Karauzum H, Ferry T, de Bentzmann S, Lina G, Bes M, Vandenesch F, et al. Comparison of adhesion and virulence of two predominant hospital-acquiredmethicillin-resistant Staphylococcus aureus clones and clonal methicillin-susceptible S.aureus isolates. Infect Immun. 2008 Nov;76(11):5133-8.
37. Amaral MM, Coelho LR, Flores RP, Souza RR, Silva-Carvalho MC, Teixeira LA, et al. The predominant variant of the Brazilian epidemic clonal complex of methicillinresistantStaphylococcus aureus has an enhanced ability to produce biofilm and toadhere to and invade airway epithelial cells. J Infect Dis. 2005 Sep 1;192(5):801-10.
38. Livorsi DJ, Daver NG, Atmar RL, Shelburne SA, White AC, Jr., Musher DM. Outcomes of treatment for hematogenous Staphylococcus aureus vertebralosteomyelitis in the MRSA ERA. J Infect. 2008 Aug;57(2):128-31.
39. Rigamonti D, Metellus P. Spinal epidural abscess. N Engl J Med. 2007 Feb 8;356(6):638; author reply -9.
40. Lazzarini L, Mader JT, Calhoun JH. Osteomyelitis in long bones. J Bone Joint Surg Am. 2004 Oct;86-A(10):2305-18.
41. Trampuz A, Zimmerli W. Diagnosis and treatment of infections associated withfracture-fixation devices. Injury. 2006 May;37 Suppl 2:S59-66.
42. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004 Oct 14;351(16):1645-54.
43. Tumeh SS, Aliabadi P, Weissman BN, McNeil BJ. Disease activity in osteomyelitis:role of radiography. Radiology. 1987 Dec;165(3):781-4.
44. Cardinal E, Bureau NJ, Aubin B, Chhem RK. Role of ultrasound in musculoskeletalinfections. Radiol Clin North Am. 2001 Mar;39(2):191-201.
45. Harcke HT, Grissom LE, Finkelstein MS. Evaluation of the musculoskeletal systemwith sonography. AJR Am J Roentgenol. 1988 Jun;150(6):1253-61.
46. Mah ET, LeQuesne GW, Gent RJ, Paterson DC. Ultrasonic features of acuteosteomyelitis in children. J Bone Joint Surg Br. 1994 Nov;76(6):969-74.
47. Babar S, Saifuddin A. MRI of the post-discectomy lumbar spine. Clin Radiol. 2002 Nov;57(11):969-81.
48. Longo M, Granata F, Ricciardi K, Gaeta M, Blandino A. Contrast-enhanced MRimaging with fat suppression in adult-onset septic spondylodiscitis. Eur Radiol. 2003 Mar;13(3):626-37.
49. Ross JS, Ruggieri P, Tkach J, Obuchowski N, Dillinger J, Masaryk TJ, et al. Lumbardegenerative disk disease: prospective comparison of conventional T2-weighted spinechoimaging and T2-weighted rapid acquisition relaxation-enhanced imaging. AJNRAm J Neuroradiol. 1993 Sep-Oct;14(5):1215-23.
50. Grand CM, Bank WO, Baleriaux D, Matos C, Levivier M, Brotchi J. Gadoliniumenhancement of vertebral endplates following lumbar disc surgery. Neuroradiology. 1993;35(7):503-5.
51. Boden SD, Davis DO, Dina TS, Sunner JL, Wiesel SW. Postoperative diskitis:distinguishing early MR imaging findings from normal postoperative disk spacechanges. Radiology. 1992 Sep;184(3):765-71.
52. Pineda C, Vargas A, Rodriguez AV. Imaging of osteomyelitis: current concepts. InfectDis Clin North Am. 2006 Dec;20(4):789-825.
53. Ledermann HP, Kaim A, Bongartz G, Steinbrich W. Pitfalls and limitations of magneticresonance imaging in chronic posttraumatic osteomyelitis. Eur Radiol. 2000;10(11):1815-23.
54. Kaim AH, Gross T, von Schulthess GK. Imaging of chronic posttraumaticosteomyelitis. Eur Radiol. 2002 May;12(5):1193-202.
55. Bureau NJ, Chhem RK, Cardinal E. Musculoskeletal infections: US manifestations.Radiographics. 1999 Nov-Dec;19(6):1585-92.
56. Venkatesh SK, Riederer B, Chhem RK, Cardinal E, Wang SC. Reactivation in posttraumaticchronic osteomyelitis: ultrasonographic findings. Can Assoc Radiol J. 2003 Jun;54(3):163-8.
57. Morrey BF, Westholm F, Schoifet S, Rand JA, Bryan RS. Long-term results of varioustreatment options for infected total knee arthroplasty. Clin Orthop Relat Res. 1989 Nov(248):120-8.
58. Atkins BL, Athanasou N, Deeks JJ, Crook DW, Simpson H, Peto TE, et al. Prospectiveevaluation of criteria for microbiological diagnosis of prosthetic-joint infection atrevision arthroplasty. The OSIRIS Collaborative Study Group. J Clin Microbiol. 1998 Oct;36(10):2932-9.
59. Ghanem E, Ketonis C, Restrepo C, Joshi A, Barrack R, Parvizi J. Periprostheticinfection: where do we stand with regard to Gram stain? Acta Orthop. 2009 Feb;80(1):37-40.
60. Trampuz A, Osmon DR, Hanssen AD, Steckelberg JM, Patel R. Molecular andantibiofilm approaches to prosthetic joint infection. Clin Orthop Relat Res. 2003 Sep(414):69-88.
61. Shmerling RH. Synovial fluid analysis. A critical reappraisal. Rheum Dis Clin NorthAm. 1994 May;20(2):503-12.
62. Kersey R, Benjamin J, Marson B. White blood cell counts and differential in synovialfluid of aseptically failed total knee arthroplasty. J Arthroplasty. 2000 Apr;15(3):301-4.
63. Trampuz A, Hanssen AD, Osmon DR, Mandrekar J, Steckelberg JM, Patel R. Synovialfluid leukocyte count and differential for the diagnosis of prosthetic knee infection. AmJ Med. 2004 Oct 15;117(8):556-62.
64. Schafer P, Fink B, Sandow D, Margull A, Berger I, Frommelt L. Prolonged bacterialculture to identify late periprosthetic joint infection: a promising strategy. Clin InfectDis. 2008 Dec 1;47(11):1403-9.
65. Spangehl MJ, Masri BA, O'Connell JX, Duncan CP. Prospective analysis ofpreoperative and intraoperative investigations for the diagnosis of infection at the sitesof two hundred and two revision total hip arthroplasties. J Bone Joint Surg Am. 1999 May;81(5):672-83.
66. Widmer AF. New developments in diagnosis and treatment of infection in orthopedicimplants. Clin Infect Dis. 2001 Sep 1;33 Suppl 2:S94-106.
67. Mackowiak PA, Jones SR, Smith JW. Diagnostic value of sinus-tract cultures inchronic osteomyelitis. Jama. 1978 Jun 30;239(26):2772-5.
68. Esteban J, Gomez-Barrena E, Cordero J, Martin-de-Hijas NZ, Kinnari TJ, Fernandez-Roblas R. Evaluation of quantitative analysis of cultures from sonicated retrievedorthopedic implants in diagnosis of orthopedic infection. J Clin Microbiol. 2008 Feb;46(2):488-92.
69. Trampuz A, Piper KE, Jacobson MJ, Hanssen AD, Unni KK, Osmon DR, et al. Sonication of removed hip and knee prostheses for diagnosis of infection. N Engl JMed. 2007 Aug 16;357(7):654-63.
70. Trampuz A, Piper KE, Hanssen AD, Osmon DR, Cockerill FR, Steckelberg JM, et al. Sonication of explanted prosthetic components in bags for diagnosis of prosthetic jointinfection is associated with risk of contamination. J Clin Microbiol. 2006 Feb;44(2):628-31.
71. Croize J, Gialanella P, Monnet D, Okada J, Orsi A, Voss A, et al. Improvedidentification of Staphylococcus aureus using a new agglutination test. Results of aninternational study. Apmis. 1993 Jun;101(6):487-91.
72. Kuusela P, Hilden P, Savolainen K, Vuento M, Lyytikainen O, Vuopio-Varkila J. Rapiddetection of methicillin-resistant Staphylococcus aureus strains not identified by slideagglutination tests. J Clin Microbiol. 1994 Jan;32(1):143-7.
73. Neville LO, Billington OJ, Kibbler CC, Gillespie SH. Methicillin resistantStaphylococcus aureus without clumping factor, protein A, and DNAse. Lancet. 1991 Aug 24;338(8765):518.
74. Fournier JM, Boutonnier A, Bouvet A. Staphylococcus aureus strains which are notidentified by rapid agglutination methods are of capsular serotype 5. J Clin Microbiol. 1989 Jun;27(6):1372-4.
75. Nakatomi Y, Sugiyama J. A rapid latex agglutination assay for the detection ofpenicillin-binding protein 2'. Microbiol Immunol. 1998;42(11):739-43.
76. van Griethuysen A, Pouw M, van Leeuwen N, Heck M, Willemse P, Buiting A, et al. Rapid slide latex agglutination test for detection of methicillin resistance inStaphylococcus aureus. J Clin Microbiol. 1999 Sep;37(9):2789-92.
77. Fenollar F, Roux V, Stein A, Drancourt M, Raoult D. Analysis of 525 samples todetermine the usefulness of PCR amplification and sequencing of the 16 S rRNA genefor diagnosis of bone and joint infections. J Clin Microbiol. 2006 Mar;44(3):1018-28.
78. Fihman V, Hannouche D, Bousson V, Bardin T, Liote F, Raskine L, et al. Improveddiagnosis specificity in bone and joint infections using molecular techniques. J Infect. 2007 Oct 26.
79. Verdier I, Gayet-Ageron A, Ploton C, Taylor P, Benito Y, Freydiere AM, et al. Contribution of a broad range polymerase chain reaction to the diagnosis ofosteoarticular infections caused by Kingella kingae: description of twenty-four recentpediatric diagnoses. Pediatr Infect Dis J. 2005 Aug;24(8):692-6.
80. Fenollar F, Fournier PE, Robert C, Raoult D. Use of genome selected repeatedsequences increases the sensitivity of PCR detection of Tropheryma whipplei. J ClinMicrobiol. 2004 Jan;42(1):401-3.
81. Dempsey KE, Riggio MP, Lennon A, Hannah VE, Ramage G, Allan D, et al. Identification of bacteria on the surface of clinically infected and non-infectedprosthetic hip joints removed during revision arthroplasties by 16 S rRNA genesequencing and by microbiological culture. Arthritis Res Ther. 2007;9(3):R46.
82. Ince A, Rupp J, Frommelt L, Katzer A, Gille J, Lohr JF. Is "aseptic" loosening of theprosthetic cup after total hip replacement due to nonculturable bacterial pathogens inpatients with low-grade infection? Clin Infect Dis. 2004 Dec 1;39(11):1599-603.
83. Tunney MM, Patrick S, Curran MD, Ramage G, Hanna D, Nixon JR, et al. Detection ofprosthetic hip infection at revision arthroplasty by immunofluorescence microscopy andPCR amplification of the bacterial 16 S rRNA gene. J Clin Microbiol. 1999 Oct;37(10):3281-90.
84. Chometon S, Benito Y, Chaker M, Boisset S, Ploton C, Berard J, et al. Specific realtimepolymerase chain reaction places Kingella kingae as the most common cause ofosteoarticular infections in young children. Pediatr Infect Dis J. 2007 May;26(5):377-81.
85. Lecouvet F, Irenge L, Vandercam B, Nzeusseu A, Hamels S, Gala JL. The etiologicdiagnosis of infectious discitis is improved by amplification-based DNA analysis.Arthritis Rheum. 2004 Sep;50(9):2985-94.
86. Becker K, Harmsen D, Mellmann A, Meier C, Schumann P, Peters G, et al. Development and evaluation of a quality-controlled ribosomal sequence database for16 S ribosomal DNA-based identification of Staphylococcus species. J Clin Microbiol. 2004 Nov;42(11):4988-95.
87. Kipp F, Kahl BC, Becker K, Baron EJ, Proctor RA, Peters G, et al. Evaluation of twochromogenic agar media for recovery and identification of Staphylococcus aureussmall-colony variants. J Clin Microbiol. 2005 Apr;43(4):1956-9.
88. Chuard C, Vaudaux PE, Proctor RA, Lew DP. Decreased susceptibility to antibiotickilling of a stable small colony variant of Staphylococcus aureus in fluid phase and onfibronectin-coated surfaces. J Antimicrob Chemother. 1997 May;39(5):603-8.
89. Kipp F, Becker K, Peters G, von Eiff C. Evaluation of different methods to detectmethicillin resistance in small-colony variants of Staphylococcus aureus. J ClinMicrobiol. 2004 Mar;42(3):1277-9.
90. Proctor RA, Kahl B, von Eiff C, Vaudaux PE, Lew DP, Peters G. Staphylococcal smallcolony variants have novel mechanisms for antibiotic resistance. Clin Infect Dis. 1998 Aug;27 Suppl 1:S68-74.
91. Nade S. Acute haematogenous osteomyelitis in infancy and childhood. J Bone JointSurg Br. 1983 Mar;65(2):109-19.
92. Esterhai JL, Jr., Gelb I. Adult septic arthritis. Orthop Clin North Am. 1991 Jul;22(3):503-14.
93. Ivey M, Clark R. Arthroscopic debridement of the knee for septic arthritis. Clin OrthopRelat Res. 1985 Oct(199):201-6.
94. Perry CR. Septic arthritis. Am J Orthop. 1999 Mar;28(3):168-78.
95. Holtom PD, Borges L, Zalavras CG. Hematogenous septic ankle arthritis. Clin OrthopRelat Res. 2008 Jun;466(6):1388-91.
96. Parisien JS. Arthroscopic management of pyarthrosis. An overview. Bull Hosp Jt DisOrthop Inst. 1987 Spring;47(1):52-7.
97. Thiery JA. Arthroscopic drainage in septic arthritides of the knee: a multicenter study.Arthroscopy. 1989;5(1):65-9.
98. Kim SJ, Choi NH, Ko SH, Linton JA, Park HW. Arthroscopic treatment of septicarthritis of the hip. Clin Orthop Relat Res. 2003 Feb(407):211-4.
99. Leslie BM, Harris JM, 3rd, Driscoll D. Septic arthritis of the shoulder in adults. J BoneJoint Surg Am. 1989 Dec;71(10):1516-22.
100. Heyde CE, Boehm H, El Saghir H, Tschoke SK, Kayser R. Surgical treatment ofspondylodiscitis in the cervical spine: a minimum 2-year follow-up. Eur Spine J. 2006 Sep;15(9):1380-7.
101. Hadjipavlou AG, Mader JT, Necessary JT, Muffoletto AJ. Hematogenous pyogenicspinal infections and their surgical management. Spine. 2000 Jul 1;25(13):1668-79.
102. Ito M, Abumi K, Kotani Y, Kadoya K, Minami A. Clinical outcome of posterolateralendoscopic surgery for pyogenic spondylodiscitis: results of 15 patients with seriouscomorbid conditions. Spine. 2007 Jan 15;32(2):200-6.
103. Simpson AH, Deakin M, Latham JM. Chronic osteomyelitis. The effect of the extent ofsurgical resection on infection-free survival. J Bone Joint Surg Br. 2001 Apr;83(3):403-7.
104. Seltzer SE. Value of computed tomography in planning medical and surgical treatmentof chronic osteomyelitis. J Comput Assist Tomogr. 1984 Jun;8(3):482-7.
105. Fitzgerald RH, Jr., Ruttle PE, Arnold PG, Kelly PJ, Irons GB. Local muscle flaps in thetreatment of chronic osteomyelitis. J Bone Joint Surg Am. 1985 Feb;67(2):175-85.
106. Levy M, Goldberg I. Treatment of chronic osteomyelitis by insertion of gentamicincontainingmethyl methacrylate. Contemp Orthop. 1981;3:1114.
107. Patzakis MJ, Abdollahi K, Sherman R, Holtom PD, Wilkins J. Treatment of chronicosteomyelitis with muscle flaps. Orthop Clin North Am. 1993 Jul;24(3):505-9.
108. Mattar R, Azze R, Ferreira M. Vascularized fibular graft for management of severeosteomyelitis of the upper extremity. Microsurgery. 1994;15:22.
109. Catagni MA, Ottaviani G, Camagni M. Treatment of massive tibial bone loss due tochronic draining osteomyelitis: fibula transport using the Ilizarov frame. Orthopedics. 2007 Aug;30(8):608-11.
110. Deirmengian C, Greenbaum J, Stern J, Braffman M, Lotke PA, Booth RE, Jr., et al. Open debridement of acute gram-positive infections after total knee arthroplasty. ClinOrthop Relat Res. 2003 Nov(416):129-34.
111. Mont MA, Waldman B, Banerjee C, Pacheco IH, Hungerford DS. Multiple irrigation,debridement, and retention of components in infected total knee arthroplasty. JArthroplasty. 1997 Jun;12(4):426-33.
112. Kaufer H, Matthews LS. Resection arthroplasty: an alternative to arthrodesis forsalvage of the infected total knee arthroplasty. Instr Course Lect. 1986;35:283-9.
113. Falahee MH, Matthews LS, Kaufer H. Resection arthroplasty as a salvage procedure fora knee with infection after a total arthroplasty. J Bone Joint Surg Am. 1987 Sep;69(7):1013-21.
114. Damron TA, McBeath AA. Arthrodesis following failed total knee arthroplasty:comprehensive review and meta-analysis of recent literature. Orthopedics. 1995 Apr;18(4):361-8.
115. Goksan SB, Freeman MA. One-stage reimplantation for infected total kneearthroplasty. J Bone Joint Surg Br. 1992 Jan;74(1):78-82.
116. Silva M, Tharani R, Schmalzried TP. Results of direct exchange or debridement of theinfected total knee arthroplasty. Clin Orthop Relat Res. 2002 Nov(404):125-31.
117. Insall JN, Thompson FM, Brause BD. Two-stage reimplantation for the salvage ofinfected total knee arthroplasty. J Bone Joint Surg Am. 1983 Oct;65(8):1087-98.
118. Durbhakula SM, Czajka J, Fuchs MD, Uhl RL. Antibiotic-loaded articulating cementspacer in the 2-stage exchange of infected total knee arthroplasty. J Arthroplasty. 2004 Sep;19(6):768-74.
119. McPherson EJ, Lewonowski K, Dorr LD. Techniques in arthroplasty. Use of anarticulated PMMA spacer in the infected total knee arthroplasty. J Arthroplasty. 1995 Feb;10(1):87-9.
120. Hanssen AD, Rand JA. Evaluation and treatment of infection at the site of a total hip orknee arthroplasty. Instr Course Lect. 1999;48:111-22.
121. Pittet D, Donaldson L. Clean Care is Safer Care: a worldwide priority. Lancet. 2005 Oct 8;366(9493):1246-7.
122. Darley ES, MacGowan AP. Antibiotic treatment of gram-positive bone and jointinfections. J Antimicrob Chemother. 2004 Jun;53(6):928-35.
123. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by communityacquiredmethicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008 Jun 1;46 Suppl 5:S368-77.
124. Al-Nammari SS, Bobak P, Venkatesh R. Methicillin resistant Staphylococcus aureusversus methicillin sensitive Staphylococcus aureus adult haematogenous septic arthritis.Arch Orthop Trauma Surg. 2007 Sep;127(7):537-42.
125. Volin SJ, Hinrichs SH, Garvin KL. Two-stage reimplantation of total joint infections: acomparison of resistant and non-resistant organisms. Clin Orthop Relat Res. 2004 Oct(427):94-100.
126. Kilgus DJ, Howe DJ, Strang A. Results of periprosthetic hip and knee infections causedby resistant bacteria. Clin Orthop Relat Res. 2002 Nov(404):116-24.
127. Salgado CD, Dash S, Cantey JR, Marculescu CE. Higher risk of failure of methicillinresistantStaphylococcus aureus prosthetic joint infections. Clin Orthop Relat Res. 2007 Aug;461:48-53.
128. Uçkay I, Lew D. Infections in Skeletal Prostheses. Bennet & Brachman's HospitalInfections 2007;5th ed:665.
129. Smilack JD, Flittie WH, Williams TW, Jr. Bone concentrations of antimicrobial agentsafter parenteral administration. Antimicrob Agents Chemother. 1976 Jan;9(1):169-71.
130. Daver NG, Shelburne SA, Atmar RL, Giordano TP, Stager CE, Reitman CA, et al. Oralstep-down therapy is comparable to intravenous therapy for Staphylococcus aureusosteomyelitis. J Infect. 2007 Jun;54(6):539-44.
131. Vuagnat A, Stern R, Lotthe A, Schuhmacher H, Duong M, Hoffmeyer P, et al. Highdose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin PharmTher. 2004 Aug;29(4):351-7.
132. Toma MB, Smith KM, Martin CA, Rapp RP. Pharmacokinetic considerations in thetreatment of methicillin-resistant Staphylococcus aureus osteomyelitis. Orthopedics. 2006 Jun;29(6):497-501.
133. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycintherapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.Arch Intern Med. 2006 Oct 23;166(19):2138-44.
134. Lazzarini L, Tramarin A, Bragagnolo L, Tositti G, Manfrin V, de LF. Three-timesweekly teicoplanin in the outpatient treatment of acute methicillin-resistantstaphylococcal osteomyelitis: a pilot study. J Chemother. 2002 Feb;14(1):71-5.
135. LeFrock JL, Ristuccia AM, Ristuccia PA, Quenzer RW, Haggerty PG, Allen JE, et al. Teicoplanin in the treatment of bone and joint infections. Teicoplanin Bone and JointCooperative Study Group, USA. Eur J Surg Suppl. 1992(567):9-13.
136. Pensotti C, Nacinovich F, Vidiella G, Carbone E, Marin M, Di Stefano C, et al. [Teicoplanin in the treatment of bone and joint infections due to methicillin resistantstaphylococci. Experience in adult patients]. Medicina (B Aires). 2002;62 Suppl 2:40-7.
137. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy ofdaptomycin for the treatment of complicated skin and skin-structure infections. ClinInfect Dis. 2004 Jun 15;38(12):1673-81.
138. Marty FM, Yeh WW, Wennersten CB, Venkataraman L, Albano E, Alyea EP, et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate duringtreatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. JClin Microbiol. 2006 Feb;44(2):595-7.
139. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety oftigecycline in the treatment of skin and skin-structure infections: results of 2 doubleblindphase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S341-53.
140. Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. Results of a doubleblind,randomized trial of ceftobiprole treatment of complicated skin and skin structureinfections caused by gram-positive bacteria. Antimicrob Agents Chemother. 2008 Jan;52(1):37-44.
141. Rouse MS, Steckelberg JM, Patel R. In vitro activity of ceftobiprole, daptomycin,linezolid, and vancomycin against methicillin-resistant staphylococci associated withendocarditis and bone and joint infection. Diagn Microbiol Infect Dis. 2007 Jul;58(3):363-5.
142. Deresinski SC. The efficacy and safety of ceftobiprole in the treatment of complicatedskin and skin structure infections: evidence from 2 clinical trials. Diagn MicrobiolInfect Dis. 2008 May;61(1):103-9.
143. Cunha B. Antibiotics in orthopaedic infections. In Orthopaedic Infection Schlossberg, D, Ed. 1998:156-74.
144. Vaudaux P, Kelley WL, Lew DP. Staphylococcus aureus small colony variants:difficult to diagnose and difficult to treat. Clin Infect Dis. 2006 Oct 15;43(8):968-70.
145. Matthews PC, Conlon CP, Berendt AR, Kayley J, Jefferies L, Atkins BL, et al. Outpatient parenteral antimicrobial therapy (OPAT): is it safe for selected patients toself-administer at home? A retrospective analysis of a large cohort over 13 years. JAntimicrob Chemother. 2007 Aug;60(2):356-62.
146. Wynn M, Dalovisio JR, Tice AD, Jiang X. Evaluation of the efficacy and safety ofoutpatient parenteral antimicrobial therapy for infections with methicillin-sensitiveStaphylococcus aureus. South Med J. 2005 Jun;98(6):590-5.
147. Galperine T, Ader F, Piriou P, Judet T, Perronne C, Bernard L. [Outpatient parenteralantimicrobial therapy (OPAT) in bone and joint infections]. Med Mal Infect. 2006 Mar;36(3):132-7.
148. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versusvancomycin in treatment of complicated skin and soft tissue infections. AntimicrobAgents Chemother. 2005 Jun;49(6):2260-6.
149. Bishop E, Melvani S, Howden BP, Charles PG, Grayson ML. Good clinical outcomesbut high rates of adverse reactions during linezolid therapy for serious infections: aproposed protocol for monitoring therapy in complex patients. Antimicrob AgentsChemother. 2006 Apr;50(4):1599-602.
150. Ferry T, Ponceau B, Simon M, Issartel B, Petiot P, Boibieux A, et al. Possiblylinezolid-induced peripheral and central neurotoxicity: report of four cases. Infection. 2005 Jun;33(3):151-4.
151. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole comparedwith vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med. 1992 Sep 1;117(5):390-8.
152. Stein A, Bataille JF, Drancourt M, Curvale G, Argenson JN, Groulier P, et al. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedicimplants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole).Antimicrob Agents Chemother. 1998 Dec;42(12):3086-91.
153. Gorwitz RJ, Jernigan DB, Powers JH, Jernigan JA, CommunityPitCfDCaPCEMoMoMit. Strategies for clinical management of MRSA in thecommunity: summary of an experts' meeting convened by the Centers for DiseaseControl and Prevention. Department of Health and Human Services, Centers forDisease Control and Prevention. 2006.
154. Proctor RA. Role of folate antagonists in the treatment of methicillin-resistantStaphylococcus aureus infection. Clin Infect Dis. 2008 Feb 15;46(4):584-93.
155. Johnson MD, Decker CF. Antimicrobial agents in treatment of MRSA infections. DisMon. 2008 Dec;54(12):793-800.
156. Ruhe JJ, Monson T, Bradsher RW, Menon A. Use of long-acting tetracyclines formethicillin-resistant Staphylococcus aureus infections: case series and review of theliterature. Clin Infect Dis. 2005 May 15;40(10):1429-34.
157. Cenizal MJ, Skiest D, Luber S, Bedimo R, Davis P, Fox P, et al. Prospectiverandomized trial of empiric therapy with trimethoprim-sulfamethoxazole ordoxycycline for outpatient skin and soft tissue infections in an area of high prevalenceof methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2007 Jul;51(7):2628-30.
158. Yourassowsky E, van der Linden MP, Lismont MJ, Crokaert F. Combination ofminocycline and rifampicin against methicillin-and gentamicin-resistantStaphylococcus aureus. J Clin Pathol. 1981 May;34(5):559-63.
159. Atkins B, Gottlieb T. Fusidic acid in bone and joint infections. Int J Antimicrob Agents. 1999 Aug;12 Suppl 2:S79-93.
160. Drancourt M, Stein A, Argenson JN, Roiron R, Groulier P, Raoult D. Oral treatment ofStaphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin incombination with rifampicin. J Antimicrob Chemother. 1997 Feb;39(2):235-40.
161. Turnidge J, Collignon P. Resistance to fusidic acid. Int J Antimicrob Agents. 1999 Aug;12 Suppl 2:S35-44.
162. Yilmaz G, Aydin K, Iskender S, Caylan R, Koksal I. Detection and prevalence ofinducible clindamycin resistance in staphylococci. J Med Microbiol. 2007 Mar;56(Pt3):342-5.
163. Panagea S, Perry JD, Gould FK. Should clindamycin be used as treatment of patientswith infections caused by erythromycin-resistant staphylococci? J AntimicrobChemother. 1999 Oct;44(4):581-2.
164. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyondurinary tract and gastrointestinal infections. Clin Infect Dis. 2008 Apr 1;46(7):1069-77.
165. Tuazon CU, Lin MY, Sheagren JN. In vitro activity of rifampin alone and incombination with nafcillin and Vancomycin against pathogenic strains ofStaphylococcus aureus. Antimicrob Agents Chemother. 1978 May;13(5):759-61.
166. Uckay I, Pittet D, Vaudaux P, Sax H, Lew D, Waldvogel F. Foreign body infectionsdue to Staphylococcus epidermidis. Ann Med. 2009;41(2):109-19.
167. Trampuz A, Zimmerli W. Antimicrobial agents in orthopaedic surgery: Prophylaxis andtreatment. Drugs. 2006;66(8):1089-105.
168. Perlroth J, Kuo M, Tan J, Bayer AS, Miller LG. Adjunctive use of rifampin for thetreatment of Staphylococcus aureus infections: a systematic review of the literature.Arch Intern Med. 2008 Apr 28;168(8):805-19.
169. Matthews PC, Dean BJ, Medagoda K, Gundle R, Atkins BL, Berendt AR, et al. Nativehip joint septic arthritis in 20 adults: delayed presentation beyond three weeks predictsneed for excision arthroplasty. J Infect. 2008 Sep;57(3):185-90.
170. Smith JW, Hasan MS. Bone and joint infections. In Mandell, Douglas and Bennett'sPrinciples and Practice of Infectious Diseases 2000;5th edn (Mandell, G. L., Bennett, J.E. & Dolin, R., Eds).1175-82.
171. Berendt AR, Lipsky B. Is this bone infected or not? Differentiating neuroosteoarthropathyfrom osteomyelitis in the diabetic foot. Curr Diab Rep. 2004 Dec;4(6):424-9.
172. Mader JT, Mohan D, Calhoun J. A practical guide to the diagnosis and management ofbone and joint infections. Drugs. 1997 Aug;54(2):253-64.
173. Al-Nammari SS, Lucas JD, Lam KS. Hematogenous methicillin-resistantStaphylococcus aureus spondylodiscitis. Spine. 2007 Oct 15;32(22):2480-6.
174. Sendi P, Bregenzer T, Zimmerli W. Spinal epidural abscess in clinical practice. Qjm. 2008 Jan;101(1):1-12.
175. Zimmerli W. Infection and musculoskeletal conditions: Prosthetic-joint-associatedinfections. Best Pract Res Clin Rheumatol. 2006 Dec;20(6):1045-63.
176. Laffer RR, Graber P, Ochsner PE, Zimmerli W. Outcome of prosthetic knee-associatedinfection: evaluation of 40 consecutive episodes at a single centre. Clin MicrobiolInfect. 2006 May;12(5):433-9.
177. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin fortreatment of orthopedic implant-related staphylococcal infections: a randomizedcontrolled trial. Foreign-Body Infection (FBI) Study Group. Jama. 1998 May20;279(19):1537-41.
178. Duncan CP, Masri BA. The role of antibiotic-loaded cement in the treatment of aninfection after a hip replacement. Instr Course Lect. 1995;44:305-13.
179. Rao N, Crossett LS, Sinha RK, Le Frock JL. Long-term suppression of infection in totaljoint arthroplasty. Clin Orthop Relat Res. 2003 Sep(414):55-60.
180. Billeter M, Zervos MJ, Chen AY, Dalovisio JR, Kurukularatne C. Dalbavancin: a novelonce-weekly lipoglycopeptide antibiotic. Clin Infect Dis. 2008 Feb 15;46(4):577-83.
181. Jauregui LE, Babazadeh S, Seltzer E, Goldberg L, Krievins D, Frederick M, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-dailylinezolid therapy for the treatment of complicated skin and skin structure infections.Clin Infect Dis. 2005 Nov 15;41(10):1407-15.
182. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Jr., Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin fortreatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004 Jun;42(6):2398-402.
183. Vandenesch F, Naimi T, Enright MC, Lina G, Nimmo GR, Heffernan H, et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis. 2003 Aug;9(8):978-84.
184. Lina G, Piemont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus inprimary skin infections and pneumonia. Clin Infect Dis. 1999 Nov;29(5):1128-32.
185. Francois P, Harbarth S, Huyghe A, Renzi G, Bento M, Gervaix A, et al. MethicillinresistantStaphylococcus aureus, Geneva, Switzerland, 1993-2005. Emerg Infect Dis. 2008 Feb;14(2):304-7.
186. Tristan A, Bes M, Meugnier H, Lina G, Bozdogan B, Courvalin P, et al. Globaldistribution of Panton-Valentine leukocidin--positive methicillin-resistantStaphylococcus aureus, 2006. Emerg Infect Dis. 2007 Apr;13(4):594-600.
187. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg InfectDis. 2001 Mar-Apr;7(2):178-82.
188. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. Methicillin-resistant S. aureus infections among patients in the emergency department.N Engl J Med. 2006 Aug 17;355(7):666-74.
189. Purcell K, Fergie J. Epidemic of community-acquired methicillin-resistantStaphylococcus aureus infections: a 14-year study at Driscoll Children's Hospital. ArchPediatr Adolesc Med. 2005 Oct;159(10):980-5.
190. Mishaan AM, Mason EO, Jr., Martinez-Aguilar G, Hammerman W, Propst JJ, Lupski JR, et al. Emergence of a predominant clone of community-acquired Staphylococcusaureus among children in Houston, Texas. Pediatr Infect Dis J. 2005 Mar;24(3):201-6.
191. Szczesiul JM, Shermock KM, Murtaza UI, Siberry GK. No decrease in clindamycinsusceptibility despite increased use of clindamycin for pediatric community-associatedmethicillin-resistant Staphylococcus aureus skin infections. Pediatr Infect Dis J. 2007 Sep;26(9):852-4.
192. Dohin B, Gillet Y, Kohler R, Lina G, Vandenesch F, Vanhems P, et al. Pediatric boneand joint infections caused by Panton-Valentine leukocidin-positive Staphylococcusaureus. Pediatr Infect Dis J. 2007 Nov;26(11):1042-8.
193. Martinez-Aguilar G, Avalos-Mishaan A, Hulten K, Hammerman W, Mason EO, Jr., Kaplan SL. Community-acquired, methicillin-resistant and methicillin-susceptibleStaphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J. 2004 Aug;23(8):701-6.
194. Stefani S, Bongiorno D, Cafiso V, Campanile F, Crapis M, Cristini F, et al. Pathotypeand susceptibility profile of a community-acquired methicillin-resistant Staphylococcusaureus strain responsible for a case of severe pneumonia. Diagn Microbiol Infect Dis. 2009 Jan;63(1):100-4.
195. Baba T, Takeuchi F, Kuroda M, Yuzawa H, Aoki K, Oguchi A, et al. Genome andvirulence determinants of high virulence community-acquired MRSA. Lancet. 2002 May 25;359(9320):1819-27.
196. Souza RR, Coelho LR, Botelho AM, Ribeiro A, Rito PN, Vieira VV, et al. Biofilmformation and prevalence of lukF-pv, seb, sec and tst genes among hospital-andcommunity-acquired isolates of some international methicillin-resistant Staphylococcusaureus lineages. Clin Microbiol Infect. 2009 Jan 31.
197. Zhu Y, Weiss EC, Otto M, Fey PD, Smeltzer MS, Somerville GA. Staphylococcusaureus biofilm metabolism and the influence of arginine on polysaccharide intercellularadhesin synthesis, biofilm formation, and pathogenesis. Infect Immun. 2007 Sep;75(9):4219-26.
198. Diep BA, Gill SR, Chang RF, Phan TH, Chen JH, Davidson MG, et al. Completegenome sequence of USA300, an epidemic clone of community-acquired meticillinresistantStaphylococcus aureus. Lancet. 2006 Mar 4;367(9512):731-9.
199. Wang R, Braughton KR, Kretschmer D, Bach TH, Queck SY, Li M, et al. Identificationof novel cytolytic peptides as key virulence determinants for community-associatedMRSA. Nat Med. 2007 Dec;13(12):1510-4.
200. Boyle-Vavra S, Daum RS. Community-acquired methicillin-resistant Staphylococcusaureus: the role of Panton-Valentine leukocidin. Lab Invest. 2007 Jan;87(1):3-9.
201. Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, Bes M, et al. Association betweenStaphylococcus aureus strains carrying gene for Panton-Valentine leukocidin andhighly lethal necrotising pneumonia in young immunocompetent patients. Lancet. 2002 Mar 2;359(9308):753-9.
202. Tristan A, Ferry T, Durand G, Dauwalder O, Bes M, Lina G, et al. Virulencedeterminants in community and hospital meticillin-resistant Staphylococcus aureus. JHosp Infect. 2007 Jun;65 Suppl 2:105-9.
203. Maree CL, Daum RS, Boyle-Vavra S, Matayoshi K, Miller LG. Community-associatedmethicillin-resistant Staphylococcus aureus isolates causing healthcare-associatedinfections. Emerg Infect Dis. 2007 Feb;13(2):236-42.
204. Miller LG, Perdreau-Remington F, Rieg G, Mehdi S, Perlroth J, Bayer AS, et al. Necrotizing fasciitis caused by community-associated methicillin-resistantStaphylococcus aureus in Los Angeles. N Engl J Med. 2005 Apr 7;352(14):1445-53.
205. Diep BA, Carleton HA, Chang RF, Sensabaugh GF, Perdreau-Remington F. Roles of34 virulence genes in the evolution of hospital-and community-associated strains ofmethicillin-resistant Staphylococcus aureus. J Infect Dis. 2006 Jun 1;193(11):1495-503.
206. Kaneko J, Kamio Y. Bacterial two-component and hetero-heptameric pore-formingcytolytic toxins: structures, pore-forming mechanism, and organization of the genes.Biosci Biotechnol Biochem. 2004 May;68(5):981-1003.
207. Szmigielski S, Prevost G, Monteil H, Colin DA, Jeljaszewicz J. Leukocidal toxins ofstaphylococci. Zentralbl Bakteriol. 1999 Apr;289(2):185-201.
208. Ma XX, Ito T, Chongtrakool P, Hiramatsu K. Predominance of clones carrying Panton-Valentine leukocidin genes among methicillin-resistant Staphylococcus aureus strainsisolated in Japanese hospitals from 1979 to 1985. J Clin Microbiol. 2006 Dec;44(12):4515-27.
209. Joubert O, Voegelin J, Guillet V, Tranier S, Werner S, Colin DA, et al. Distinctionbetween Pore Assembly by Staphylococcal alpha-Toxin versus Leukotoxins. J BiomedBiotechnol. 2007;2007:25935.
210. Valeva A, Walev I, Pinkernell M, Walker B, Bayley H, Palmer M, et al. Transmembrane beta-barrel of staphylococcal alpha-toxin forms in sensitive but not inresistant cells. Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11607-11.
211. Genestier AL, Michallet MC, Prevost G, Bellot G, Chalabreysse L, Peyrol S, et al. Staphylococcus aureus Panton-Valentine leukocidin directly targets mitochondria andinduces Bax-independent apoptosis of human neutrophils. J Clin Invest. 2005 Nov;115(11):3117-27.
212. Konig B, Koller M, Prevost G, Piemont Y, Alouf JE, Schreiner A, et al. Activation ofhuman effector cells by different bacterial toxins (leukocidin, alveolysin, anderythrogenic toxin A): generation of interleukin-8. Infect Immun. 1994 Nov;62(11):4831-7.
213. Konig B, Prevost G, Piemont Y, Konig W. Effects of Staphylococcus aureusleukocidins on inflammatory mediator release from human granulocytes. J Infect Dis. 1995 Mar;171(3):607-13.
214. Colin DA, Monteil H. Control of the oxidative burst of human neutrophils bystaphylococcal leukotoxins. Infect Immun. 2003 Jul;71(7):3724-9.
215. de Bentzmann S, Tristan A, Etienne J, Brousse N, Vandenesch F, Lina G. Staphylococcus aureus isolates associated with necrotizing pneumonia bind to basementmembrane type I and IV collagens and laminin. J Infect Dis. 2004 Oct 15;190(8):1506-15.
216. Grojec PL, Jeljaszewicz J. Effect of staphylococcal leukocidin on mouse leukocytesystem. Zentralbl Bakteriol Mikrobiol Hyg [A]. 1981 Nov;250(4):446-55.
217. Szmigielski S, Jeljaszewicz J, Wilczynski J, Korbecki M. Reaction of rabbit leucocytesto staphylococcal (Panton-Valentine) leucocidin in vivo. J Pathol Bacteriol. 1966 Apr;91(2):599-604.
218. Ward PD, Turner WH. Identification of staphylococcal Panton-Valentine leukocidin asa potent dermonecrotic toxin. Infect Immun. 1980 May;28(2):393-7.
219. Labandeira-Rey M, Couzon F, Boisset S, Brown EL, Bes M, Benito Y, et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia.Science. 2007 Feb 23;315(5815):1130-3.
220. adiou C, Dumitrescu O, Croze M, Gillet Y, Dohin B, Slayman DH, et al. Panton-Valentine leukocidin is expressed at toxic levels in human skin abscesses. ClinMicrobiol Infect. 2008 Dec;14(12):1180-3.
221. Young MF. Bone matrix proteins: their function, regulation, and relationship toosteoporosis. Osteoporos Int. 2003;14 Suppl 3:S35-42.
222. Clark BR, Keating A. Biology of bone marrow stroma. Ann N Y Acad Sci. 1995 Dec29;770:70-8.
223. Tristan A, Benito Y, Montserret R, Boisset S, Dusserre E, Penin F, et al. The signalpeptide of Staphylococcus aureus panton valentine leukocidin LukS componentmediates increased adhesion to heparan sulfates. PLoS ONE. 2009;4(4):e5042.
224. Gomez MI, Lee A, Reddy B, Muir A, Soong G, Pitt A, et al. Staphylococcus aureusprotein A induces airway epithelial inflammatory responses by activating TNFR1. NatMed. 2004 Aug;10(8):842-8.
225. Diep BA, Palazzolo-Ballance AM, Tattevin P, Basuino L, Braughton KR, Whitney AR,et al. Contribution of Panton-Valentine leukocidin in community-associated methicillinresistantStaphylococcus aureus pathogenesis. PLoS ONE. 2008;3(9):e3198.
226. Gonzalez BE, Martinez-Aguilar G, Hulten KG, Hammerman WA, Coss-Bu J, Avalos-Mishaan A, et al. Severe Staphylococcal sepsis in adolescents in the era of communityacquiredmethicillin-resistant Staphylococcus aureus. Pediatrics. 2005 Mar;115(3):642-8.
227. Deurenberg RH, Stobberingh EE. The evolution of Staphylococcus aureus. Infect GenetEvol. 2008 Dec;8(6):747-63.
228. Lee SM, Ender M, Adhikari R, Smith JM, Berger-Bachi B, Cook GM. Fitness cost ofstaphylococcal cassette chromosome mec in methicillin-resistant Staphylococcus aureusby way of continuous culture. Antimicrob Agents Chemother. 2007 Apr;51(4):1497-9.
229. Diep BA, Stone GG, Basuino L, Graber CJ, Miller A, des Etages SA, et al. The argininecatabolic mobile element and staphylococcal chromosomal cassette mec linkage:convergence of virulence and resistance in the USA300 clone of methicillin-resistantStaphylococcus aureus. J Infect Dis. 2008 Jun 1;197(11):1523-30.
230. Diep BA, Otto M. The role of virulence determinants in community-associated MRSApathogenesis. Trends Microbiol. 2008 Aug;16(8):361-9.
231. Kaito C, Omae Y, Matsumoto Y, Nagata M, Yamaguchi H, Aoto T, et al. A novel gene,fudoh, in the SCCmec region suppresses the colony spreading ability and virulence ofStaphylococcus aureus. PLoS ONE. 2008;3(12):e3921.
232. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, et al. Invasivemethicillin-resistant Staphylococcus aureus infections in the United States. Jama. 2007 Oct 17;298(15):1763-71.
233. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993 Dec30;329(27):2002-12.
234. Bubeck Wardenburg J, Bae T, Otto M, Deleo FR, Schneewind O. Poring over pores:alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureuspneumonia. Nat Med. 2007 Dec;13(12):1405-6.
235. Kaplan SL. Community-acquired methicillin-resistant Staphylococcus aureus infectionsin children. Semin Pediatr Infect Dis. 2006 Jul;17(3):113-9.
236. Browne LP, Mason EO, Kaplan SL, Cassady CI, Krishnamurthy R, Guillerman RP. Optimal imaging strategy for community-acquired Staphylococcus aureusmusculoskeletal infections in children. Pediatr Radiol. 2008 Aug;38(8):841-7.
237. Ferry T, Etienne J. Community acquired MRSA in Europe. Bmj. 2007 Nov10;335(7627):947-8.
238. Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, et al. Comparison of community-and health care-associated methicillin-resistantStaphylococcus aureus infection. Jama. 2003 Dec 10;290(22):2976-84.
239. Betz RR, Cooperman DR, Wopperer JM, Sutherland RD, White JJ, Jr., Schaaf HW, etal. Late sequelae of septic arthritis of the hip in infancy and childhood. J PediatrOrthop. 1990 May-Jun;10(3):365-72.
240. Blickman JG, van Die CE, de Rooy JW. Current imaging concepts in pediatricosteomyelitis. Eur Radiol. 2004 Mar;14 Suppl 4:L55-64.
241. Arnold SR, Elias D, Buckingham SC, Thomas ED, Novais E, Arkader A, et al. Changing patterns of acute hematogenous osteomyelitis and septic arthritis: emergenceof community-associated methicillin-resistant Staphylococcus aureus. J Pediatr Orthop. 2006 Nov-Dec;26(6):703-8.
242. Pannaraj PS, Hulten KG, Gonzalez BE, Mason EO, Jr., Kaplan SL. Infectivepyomyositis and myositis in children in the era of community-acquired, methicillinresistantStaphylococcus aureus infection. Clin Infect Dis. 2006 Oct 15;43(8):953-60.
243. Gonzalez BE, Teruya J, Mahoney DH, Jr., Hulten KG, Edwards R, Lamberth LB, et al. Venous thrombosis associated with staphylococcal osteomyelitis in children. Pediatrics. 2006 May;117(5):1673-9.
244. Kaplan SL, Hulten KG, Gonzalez BE, Hammerman WA, Lamberth L, Versalovic J, etal. Three-year surveillance of community-acquired Staphylococcus aureus infections inchildren. Clin Infect Dis. 2005 Jun 15;40(12):1785-91.
245. El-Maghraby TA, Moustafa HM, Pauwels EK. Nuclear medicine methods forevaluation of skeletal infection among other diagnostic modalities. Q J Nucl Med MolImaging. 2006 Sep;50(3):167-92.
246. Loffler CA, Macdougall C. Update on prevalence and treatment of methicillin-resistantStaphylococcus aureus infections. Expert Rev Anti Infect Ther. 2007 Dec;5(6):961-81.
247. Cole WG, Dalziel RE, Leitl S. Treatment of acute osteomyelitis in childhood. J BoneJoint Surg Br. 1982;64(2):218-23.
248. Meller I, Manor Y, Bar-Ziv J, Torok G. Pediatric update #8. Acute hematogenousosteomyelitis in children. Long-term results of surgical treatment. Orthop Rev. 1989 Jul;18(7):824-31.
249. Infection of the musculoskeletal system, in Tachdjian's pediatric orthopaedics. JA Herring ed, Saunders.Philadelphia, 2008, 4th edition.:2089-177.
250. Morrissy RT. Bone and joint sepsis. In Lovell and Winter's pediatric orthopaedics.ed, Lippincott, Philadelphia, 2001.(5th edition):459-505.
251. El-Sayed AM. Treatment of early septic arthritis of the hip in children: comparison ofresults of open arthrotomy versus arthroscopic drainage. J Child Orthop. 2008 Jun;2(3):229-37.
252. Givon U, Liberman B, Schindler A, Blankstein A, Ganel A. Treatment of septicarthritis of the hip joint by repeated ultrasound-guided aspirations. J Pediatr Orthop. 2004 May-Jun;24(3):266-70.
253. Kaplan SL. Osteomyelitis in children. Infect Dis Clin North Am. 2005 Dec;19(4):787-97, vii.
254. Hawkshead JJ, 3rd, Patel NB, Steele RW, Heinrich SD. Comparative severity ofpediatric osteomyelitis attributable to methicillin-resistant versus methicillin-sensitiveStaphylococcus aureus. J Pediatr Orthop. 2009 Jan-Feb;29(1):85-90.
255. Dombrowski JC, Winston LG. Clinical failures of appropriately-treated methicillinresistantStaphylococcus aureus infections. J Infect. 2008 Aug;57(2):110-5.
256. Bocchini CE, Hulten KG, Mason EO, Jr., Gonzalez BE, Hammerman WA, Kaplan SL. Panton-Valentine leukocidin genes are associated with enhanced inflammatoryresponse and local disease in acute hematogenous Staphylococcus aureus osteomyelitisin children. Pediatrics. 2006 Feb;117(2):433-40.
257. Martinez-Aguilar G, Hammerman WA, Mason EO, Jr., Kaplan SL. Clindamycintreatment of invasive infections caused by community-acquired, methicillin-resistantand methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J. 2003 Jul;22(7):593-8.
258. Frank AL, Marcinak JF, Mangat PD, Tjhio JT, Kelkar S, Schreckenberger PC, et al.Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections inchildren. Pediatr Infect Dis J. 2002 Jun;21(6):530-4.
259. Sattler CA, Mason EO, Jr., Kaplan SL. Prospective comparison of risk factors anddemographic and clinical characteristics of community-acquired, methicillin-resistantversus methicillin-susceptible Staphylococcus aureus infection in children. PediatrInfect Dis J. 2002 Oct;21(10):910-7.
260. Wu KC, Chiu HH, Wang JH, Lee NS, Lin HC, Hsieh CC, et al. Characteristics ofcommunity-acquired methicillin-resistant Staphylococcus aureus in infants and childrenwithout known risk factors. J Microbiol Immunol Infect. 2002 Mar;35(1):53-6.
261. Lamp KC, Friedrich LV, Mendez-Vigo L, Russo R. Clinical experience withdaptomycin for the treatment of patients with osteomyelitis. Am J Med. 2007 Oct;120(10 Suppl 1):S13-20.
262. Daum RS. Clinical practice. Skin and soft-tissue infections caused by methicillinresistantStaphylococcus aureus. N Engl J Med. 2007 Jul 26;357(4):380-90.
263. Popovich K, Hota B, Rice T, Aroutcheva A, Weinstein RA. Phenotypic prediction rulefor community-associated methicillin-resistant Staphylococcus aureus. J ClinMicrobiol. 2007 Jul;45(7):2293-5.
264. Hageman JC, Patel J, Franklin P, Miscavish K, McDougal L, Lonsway D, et al. Occurrence of a USA300 vancomycin-intermediate Staphylococcus aureus. DiagnMicrobiol Infect Dis. 2008 Dec;62(4):440-2.
265. Ohlsen K, Ziebuhr W, Koller KP, Hell W, Wichelhaus TA, Hacker J. Effects ofsubinhibitory concentrations of antibiotics on alpha-toxin (hla) gene expression ofmethicillin-sensitive and methicillin-resistant Staphylococcus aureus isolates.Antimicrob Agents Chemother. 1998 Nov;42(11):2817-23.
266. Dumitrescu O, Boisset S, Badiou C, Bes M, Benito Y, Reverdy ME, et al. Effect ofantibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.Antimicrob Agents Chemother. 2007 Apr;51(4):1515-9.
267. Dumitrescu ON, Protti DA, Majumdar S, Zeilhofer HU, Wassle H. Ionotropicglutamate receptors of amacrine cells of the mouse retina. Vis Neurosci. 2006 Jan-Feb;23(1):79-90.
268. Mukhtar TA, Wright GD. Streptogramins, oxazolidinones, and other inhibitors ofbacterial protein synthesis. Chem Rev. 2005 Feb;105(2):529-42.
269. Sabharwal V, Marchant CD. Fluoroquinolone use in children. Pediatr Infect Dis J. 2006 Mar;25(3):257-8.